Table 2.
The study plan
| Screening | Immediate phase (intravenous drip of salvianolate for 30 min) | In-hospital follow-up | |
|---|---|---|---|
| Day 1 | Day 1 | Day 7 | |
| Inclusion/exclusion criteria | X | ||
| Informed consent | X | ||
| Randomization | X | ||
| Demographic information | X | ||
| Medical history | X | ||
| Vital signs | X | X | X |
| Physical examination | X | X | |
| Concomitant medications | X | X | |
| CBC | X | X | |
| Scr, BUN, UA | X | X | |
| K, Na, Cl | X | X | |
| ALT, AST, BIL | X | X | |
| Fasting glucose/lipids | X | X | |
| cTnT/cTnI | X | X | |
| Electrocardiography | X | X | |
| Echocardiography | X | X | |
| Medication | |||
| Salvianolate injection | X | X | |
| End points | |||
| Seattle angina scale | X | X | |
| Quality of life scale | X | X | |
| Holter electrocardiography | X | X | |
| 6-min walk test | X | X | |
| IMR | X | X | |
CBC, complete blood count; Scr, serum creatinine; BUN, blood urea nitrogen; UA, uric acid; K, potassium; Na, sodium; Cl, chloride; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BIL, bilirubin; cTnT/cTnI, cardiac troponin T/I; IMR, index of microcirculatory resistance